PharmacoMicrobiomics: The Drug-Microbiome Portal

How Bugs Modulate Drugs?

Launched on 11/11/11; Current Release 1.5 (21 Mar 2021): Spring of Hope! (Release History)

Detailed View

Summary Gut microbes (species: Lactobacillus reuteri) decrease Resveratrol 's toxicity.
Resveratrol (PubChem CID: 445154)
Lactobacillus reuteri (Tax ID: 1598)
decrease toxicity
Resveratrol is a natural phenolic compound with anti-inflammatory properties. Resveratrol can reduce mortality of acute respiratory distress syndrome (ARDS) by attenuating Staphylococcal Enterotoxin B antigen. Staphylococcal Enterotoxin B induces inflammatory cytokines which result in 100% mortality in C3H/HeJ mice and increases pathogenic Proteobacteria phylum and Propionibacterium acnes species in the lungs. Treatment with resveratrol can attenuate Staphylococcal Enterotoxin B and increase probiotic Actinobacteria phylum, Tenericutes phylum, and Lactobacillus reuteri species in both the colon and lungs. Mice transplanted microbiota with L. reuterithen and injected with Staphylococcal Enterotoxin B then treated with resveratrol shows inhibition of production of pro-inflammatory cytokines as IFN-γ and IL-17 but increasing the anti-inflammatory IL-10. furthermore, decreasing lung infiltrate to mononuclear cells, cytotoxic CD8+ T cells, NKT cells, Th1 cells, and Th17 cells, but an increase in the population of regulatory T cells (Tregs) and Th3 cells, and increase in the survival of mice from SEB-mediated ARDS.

Browse Drug-Microbiome Relationship